January |
|
Deal title | Principal company | Partner company | Amount awarded ($M) | Date |
US AMRA to award 3M funding to develop solutions for infection prevention, wound management and wound healing after traumatic injury | 3M Co. | US Army Medical Research Acquisition Activity | $34.20 | 1/10/2024 |
BARDA to award ATCC funding to develop vaccines and therapeutics against COVID-19 | American Type Culture Collection | Biomedical Advanced Research and Development Authority | $87.00 | 1/4/2024 |
Target ALS Foundation to award Dewpoint funding to evaluate the in vivo efficacy of C-mods therapeutics for TDP-43 condensatopathy in ALS | Dewpoint Therapeutics Inc. | Target ALS Foundation Inc. | Payment unspecified | 1/16/2024 |
US DoD to award Factor Bioscience funding to develop and commercialize mRNA gene-edited cell therapy candidates against Duchenne muscular dystrophy | Factor Bioscience Inc. | U.S. Department of Defense | Payment unspecified | 1/9/2024 |
KDDF to award HK inno.N funding to support the development of IN-B005 for cancer treatment | HK inno.N Corp. | Korea Drug Development Fund | Payment unspecified | 1/16/2024 |
CARB-X to award Intravacc funding to develop OMV based preventive vaccine against Neisseria gonorrhoeae infection | Intravacc BV | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator | $0.63 | 1/16/2024 |
CEPI to award Lemonex grant to advance DegradaBALL mRNA vaccine delivery against future pandemic infections | Lemonex Inc. | Coalition for Epidemic Preparedness Innovations | $4.60 | 1/4/2024 |
RSRT to award Proqr funding to develop Axiomer-based therapeutic against Rett syndrome | Proqr Therapeutics NV | Rett Syndrome Research Trust | $1.00 | 1/5/2024 |
Bill & Melinda Gates Foundation to award Sail Biomedicines funding to develop eRNA vaccines and mAb therapies against malaria | Sail Biomedicines Inc. | Bill & Melinda Gates Foundation Trust | Payment unspecified | 1/3/2024 |
Carlos III Health Institute to award VHIO funding to conduct research on various diseases | Vall d'Hebron Institut d'Oncologia | Instituto de Salud Carlos III | $2.58 | 1/8/2024 |